AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17553993 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study 17553993 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral DLPFC tDCS (both anodal and cathodal)
Number of subjects: 0
Study 15036491 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate (E2V) and medroxyprogesterone acetate (MPA) treatment for 12 or 14 days with combinations of 1 mg or 2 mg E2V and 2.5 mg or 5 mg MPA.
Number of subjects: 46
Study 15036491 — intervention group
Group type: COMPARATOR
Intervention: Control group (younger women under 60 years)
Number of subjects: 46
Study 11485531 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (119 patients)
Number of subjects: 241
Study 11485531 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (122 patients)
Number of subjects: 241
Study 9727762 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 88
Study 9727762 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 88
Study 9727762 — intervention group
Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 88
Study 8047805 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam, 50 mg/kg.day for 5 days
Number of subjects: 80
Study 8047805 — intervention group
Group type: COMPARATOR
Intervention: Nalidixic acid, 60 mg/kg.day for 5 days
Number of subjects: 80
Study 3196080 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet high in polyunsaturated fatty acids supplemented with eicosapentaenoic and docosahexaenoic acids
Number of subjects: 12
Study 3196080 — intervention group
Group type: COMPARATOR
Intervention: Diet high in saturated fatty acids
Number of subjects: 12
Study 31974914 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 32
Study 31974914 — intervention group
Group type: COMPARATOR
Intervention: Non-eradication
Number of subjects: 32
Study 30106530 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step 0.454% SnF₂ dentifrice and 3% H₂O₂ gel sequence
Number of subjects: 49
Study 30106530 — intervention group
Group type: COMPARATOR
Intervention: Regular anticavity toothpaste control
Number of subjects: 49
Study 28942806 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care (low intensity, standard CBT, individually tailored treatment)
Number of subjects: 281
Study 28942806 — intervention group
Group type: COMPARATOR
Intervention: Single, empirically validated cognitive-behavioral therapy (CBT) program
Number of subjects: 281
Study 26299236 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 304
Study 26299236 — intervention group
Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 304
Study 23589527 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin infusion at 0.2 nmol kg(‐1) h(‐1)
Number of subjects: 16
Study 23589527 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin infusion at 0.6 nmol kg(‐1) h(‐1)
Number of subjects: 16
Study 23589527 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 16
Study 21248722 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 93
Study 21248722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 18088076 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil HCl (Aricept)
Number of subjects: 23
Study 18088076 — intervention group
Group type: EXPERIMENTAL
Intervention: Open donepezil treatment
Number of subjects: 23
Study 18088076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 17315802 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 1%
Number of subjects: 0
Study 17315802 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 2%
Number of subjects: 0
Study 17315802 — intervention group
Group type: COMPARATOR
Intervention: Dakin's liquid + urea peroxide
Number of subjects: 0
Study 17315802 — intervention group
Group type: COMPARATOR
Intervention: Dakin's liquid
Number of subjects: 0
Study 17315802 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 0
Study 17315802 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 1% and 2%
Number of subjects: 0
Study 12798838 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary care (MDC)
Number of subjects: 98
Study 12798838 — intervention group
Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 98
Study 12798838 — intervention group
Group type: EXPERIMENTAL
Intervention: MDC
Number of subjects: 98
Study 10556657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankylosing spondylitis patients
Number of subjects: 18
Study 8740617 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group, provided with a self‐instructional booklet of pain control techniques
Number of subjects: 48
Study 8740617 — intervention group
Group type: COMPARATOR
Intervention: Citizenship group, to control for reading a booklet
Number of subjects: 48
Study 8740617 — intervention group
Group type: COMPARATOR
Intervention: Control group with no advanced preparation
Number of subjects: 48
Study 8740617 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning time of 180 sec
Number of subjects: 48
Study 8740617 — intervention group
Group type: EXPERIMENTAL
Intervention: High scorers on perceived self‐efficacy
Number of subjects: 48
Study 1907422 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous nitroglycerin (33 micrograms/min)
Number of subjects: 16
Study 1907422 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous nitroglycerin (133 micrograms/min)
Number of subjects: 16
Study 6615094 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 106
Study 6615094 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counseling
Number of subjects: 106
Study 6615094 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study 6615094 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 106
Study 6615094 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 106
Study 31063550 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid users (OU)
Number of subjects: 129
Study 31063550 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone-maintained smokers
Number of subjects: 129
Study 30415593 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab 600 mg every 24 weeks for ⩾120 weeks
Number of subjects: 0
Study 30415593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30415593 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab 600 mg
Number of subjects: 0
Study 27835715 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive ziprasidone (escitalopram + ziprasidone, n = 71)
Number of subjects: 139
Study 27835715 — intervention group
Group type: COMPARATOR
Intervention: Placebo (escitalopram + placebo, n = 68)
Number of subjects: 139
Study 25727243 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward leaning body posture with inhalation of 200 μgr salbutamol
Number of subjects: 41
Study 25727243 — intervention group
Group type: COMPARATOR
Intervention: Standard body posture with inhalation of 200 μgr salbutamol
Number of subjects: 41
Study 23293168 — intervention group
Group type: EXPERIMENTAL
Intervention: CAS + CABG
Number of subjects: 174
Study 23293168 — intervention group
Group type: COMPARATOR
Intervention: Isolated CABG
Number of subjects: 174
Study 21183586 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Number of subjects: 9
Study 21183586 — intervention group
Group type: COMPARATOR
Intervention: Meat diet
Number of subjects: 9
Study 18235100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT)
Number of subjects: 2707
Study 18235100 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 2707
Study 16996006 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronavigator-guided PRTTG
Number of subjects: 54
Study 16996006 — intervention group
Group type: COMPARATOR
Intervention: PRTTG without neuronavigation (Control)
Number of subjects: 54
Study 14617545 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular pacing (RVP) patients with drug resistant heart failure (group B)
Number of subjects: 16
Study 14617545 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventricular electromechanical delay or intra‐LV electromechanical delay > 50 ms in RVP patients
Number of subjects: 16
Study 14617545 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 16
Study 14617545 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG criteria for ventricular mechanical asynchrony identification in group B
Number of subjects: 16
Study 10845431 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg once daily for 7 days)
Number of subjects: 493
Study 10845431 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil (250 mg twice daily for 10 days)
Number of subjects: 493
Study 10845431 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 493
Study 10845431 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil
Number of subjects: 493
Study 9157756 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine (12 mg/day)
Number of subjects: 19
Study 9157756 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 mg/day)
Number of subjects: 19
Study 8228368 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 65
Study 8228368 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) (160/800 mg)
Number of subjects: 65
Study 8228368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 3942335 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 5 micrograms X kg‐1 po in addition to standard premedication 90 min before estimated induction time
Number of subjects: 24
Study 3942335 — intervention group
Group type: COMPARATOR
Intervention: Standard premedication
Number of subjects: 24
Study 30753384 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (NTZ) 600 mg twice daily for age ≥12 years; 200 mg for age 4-11 years; 100 mg for age 1-3 years for 5 days
Number of subjects: 260
Study 30753384 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 260
Study 30753384 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (NTZ)
Number of subjects: 260
Study 30753384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 30558159 — intervention group
Group type: EXPERIMENTAL
Intervention: WB+BM- (Wheat Bran without Barley)
Number of subjects: 60
Study 30558159 — intervention group
Group type: EXPERIMENTAL
Intervention: WB-BM+ (Barley without Wheat Bran)
Number of subjects: 60
Study 30558159 — intervention group
Group type: COMPARATOR
Intervention: WB-BM- (Control group with neither Wheat Bran nor Barley)
Number of subjects: 60
Study 27477534 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 per cent clotrimazole solution
Number of subjects: 120
Study 27477534 — intervention group
Group type: COMPARATOR
Intervention: 3 per cent boric acid in 70 per cent alcohol
Number of subjects: 120
Study 23726985 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate reporting
Number of subjects: 598
Study 23726985 — intervention group
Group type: COMPARATOR
Intervention: Delayed reporting
Number of subjects: 598
Study 22915174 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-km treadmill walking test (76 ± 8 % VO(2max))
Number of subjects: 19
Study 22915174 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaustive treadmill testing
Number of subjects: 19
Study 22915174 — intervention group
Group type: COMPARATOR
Intervention: Resting control condition
Number of subjects: 19
Study 20505433 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants recruited by NIA-funded AD research centers
Number of subjects: 769
Study 20505433 — intervention group
Group type: COMPARATOR
Intervention: Participants recruited by commercial clinical sites
Number of subjects: 769
Study 20505433 — intervention group
Group type: COMPARATOR
Intervention: Participants with less than college education
Number of subjects: 769
Study 20505433 — intervention group
Group type: COMPARATOR
Intervention: Participants with Hamilton Depression score of 6 or more
Number of subjects: 769
Study 20505433 — intervention group
Group type: COMPARATOR
Intervention: Unmarried males
Number of subjects: 769
Study 20505433 — intervention group
Group type: COMPARATOR
Intervention: Nonwhites
Number of subjects: 769
Study 18412024 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (Loprax) 400 mg cefixime
Number of subjects: 24
Study 18412024 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation 400 mg cefixime
Number of subjects: 24
Study 16361658 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 135
Study 16361658 — intervention group
Group type: COMPARATOR
Intervention: Laser iridotomy
Number of subjects: 135
Study 16361658 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of symptoms
Number of subjects: 135
Study 16361658 — intervention group
Group type: EXPERIMENTAL
Intervention: Time taken to resolution of APAC
Number of subjects: 135
Study 14512004 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Normovolaemic Haemodilution (ANH)
Number of subjects: 34
Study 14512004 — intervention group
Group type: COMPARATOR
Intervention: Control (standard fluid management)
Number of subjects: 34
Study 11236168 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE-guided cardioversion
Number of subjects: 0
Study 11236168 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier cardioversion using TEE-guided approach
Number of subjects: 0
Study 11236168 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation during and after restoration of sinus rhythm
Number of subjects: 0
Study 11236168 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification using TEE
Number of subjects: 0
Study 8624641 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg weekly
Number of subjects: 29
Study 8624641 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg weekly, increased to 25 mg for poor responders
Number of subjects: 29
Study 8624641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 1428643 — intervention group
Group type: EXPERIMENTAL
Intervention: Various antenatal care practices
Number of subjects: 0
Study 1428643 — intervention group
Group type: COMPARATOR
Intervention: Practices not evaluated or shown to be ineffective
Number of subjects: 0
Study 2869996 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin regimen designed to maintain near‐normal glycemic levels
Number of subjects: 278
Study 2869996 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with up to two insulin injections daily
Number of subjects: 278
Study 31475795 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization with PCI of angiographically significant nonculprit lesions
Number of subjects: 4041
Study 31475795 — intervention group
Group type: COMPARATOR
Intervention: Culprit-lesion-only PCI
Number of subjects: 4041
Study 30180960 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination simvastatin (40 mg)/ezetimibe (10 mg)
Number of subjects: 14192
Study 30180960 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (40 mg) alone
Number of subjects: 14192
Study 30180960 — intervention group
Group type: EXPERIMENTAL
Intervention: No HF
Number of subjects: 14192
Study 30180960 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐existing HF
Number of subjects: 14192
Study 30180960 — intervention group
Group type: EXPERIMENTAL
Intervention: De novo HF
Number of subjects: 14192
Study 27206235 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 50
Study 27206235 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 50
Study 24021896 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac ophthalmic solution 0.07%
Number of subjects: 440
Study 24021896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study 21466102 — intervention group
Group type: EXPERIMENTAL
Intervention: Situational salience
Number of subjects: 0
Study 21466102 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual cues present
Number of subjects: 0
Study 21466102 — intervention group
Group type: COMPARATOR
Intervention: Distinctiveness (architectural landmarks)
Number of subjects: 0
Study 16060219 — intervention group
Group type: EXPERIMENTAL
Intervention: NaFeEDTA-fortified soy sauce (29.6 mg Fe/100 ml)
Number of subjects: 14000
Study 16060219 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 14000
Study 12398960 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg/day
Number of subjects: 332
Study 12398960 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg/day plus atorvastatin 10 mg/day
Number of subjects: 332
Study 12398960 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg/day plus atorvastatin 20 mg/day
Number of subjects: 332
Study 12398960 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone plus placebo
Number of subjects: 332
Study 9611469 — intervention group
Group type: EXPERIMENTAL
Intervention: Saucer-shaped Class II resin composite restorations
Number of subjects: 51
Study 9611469 — intervention group
Group type: COMPARATOR
Intervention: Caries and technical deficiencies
Number of subjects: 51
Study 7989408 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin treatment
Number of subjects: 26
Study 2538499 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium, 4 mg
Number of subjects: 12
Study 2538499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 4616804 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxolinic acid (750 mg twice-daily for 14 days)
Number of subjects: 60
Study 4616804 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin (500 mg 3-times daily for 14 days)
Number of subjects: 60
Study 12611485 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF 5 microg/kg per day
Number of subjects: 61
Study 12611485 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF 5 microg/kg per day
Number of subjects: 61
Study 12611485 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 61
Study 12611485 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF
Number of subjects: 61
Study 30814485 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation at home
Number of subjects: 0
Study 30326972 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency ultrasonic debridement
Number of subjects: 10
Study 30326972 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical sharps debridement
Number of subjects: 10
Study 30326972 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 10
Study 27237754 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe relapse(s)
Number of subjects: 959
Study 27237754 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapses leading to hospitalization
Number of subjects: 959
Study 25408387 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of BMI and AEC in lumbar spiral CT scans
Number of subjects: 100
Study 25408387 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup 5 of group B
Number of subjects: 100
Study 25408387 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup 4 and subgroup 5 parameters
Number of subjects: 100
Study 22217457 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 1622
Study 22217457 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis
Number of subjects: 1622
Study 22217457 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1622
Study 20124118 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 129
Study 20124118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 20124118 — intervention group
Group type: COMPARATOR
Intervention: Problem Solving Therapy
Number of subjects: 129
Study 17630481 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (40, 80, or 160 microg/kg)
Number of subjects: 399
Study 17630481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study 15848703 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG-Fresenius (4-6 mg/kg body weight)
Number of subjects: 105
Study 15848703 — intervention group
Group type: COMPARATOR
Intervention: Thymoglobulin (1.5-2.5 mg/kg body weight)
Number of subjects: 105
Study 11932960 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole with 400 mg of didanosine (encapsulated, enteric-coated bead formulation)
Number of subjects: 0
Study 11932960 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg fluconazole with 400 mg of didanosine (encapsulated, enteric-coated bead formulation)
Number of subjects: 0
Study 9798189 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac-gentamicin eye drops
Number of subjects: 196
Study 9798189 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin eye drops
Number of subjects: 196
Study 7665655 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR detection of Haemophilus influenzae in nasopharyngeal secretions
Number of subjects: 213
Study 7665655 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR detection of Haemophilus influenzae in middle ear effusions (MEEs)
Number of subjects: 213
Study 7665655 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR detection of P6 gene DNA in MEEs
Number of subjects: 213
Study 2545979 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy (CAV)
Number of subjects: 112
Study 2545979 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy using three different drug combinations
Number of subjects: 112
Study 795456 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (Inderal) 20 mg
Number of subjects: 12
Study 795456 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (Inderal) 40 mg
Number of subjects: 12
Study 795456 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (Inderal) 80 mg
Number of subjects: 12
Study 795456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12